Taysha Gene Therapies (NASDAQ:TSHA) Reaches New 52-Week High – Time to Buy?

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) hit a new 52-week high on Monday . The company traded as high as $5.96 and last traded at $5.8650, with a volume of 816473 shares changing hands. The stock had previously closed at $5.49.

Wall Street Analysts Forecast Growth

TSHA has been the subject of several research reports. The Goldman Sachs Group set a $11.00 price target on shares of Taysha Gene Therapies in a research report on Thursday, December 4th. Citigroup reiterated an “outperform” rating on shares of Taysha Gene Therapies in a research report on Wednesday, November 5th. Chardan Capital reiterated a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, December 15th. Finally, JMP Securities set a $8.00 price objective on Taysha Gene Therapies in a report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $10.42.

Taysha Gene Therapies Stock Up 5.7%

The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -17.59 and a beta of 1.06. The firm’s fifty day moving average is $4.77 and its 200-day moving average is $3.58. The company has a debt-to-equity ratio of 0.23, a current ratio of 10.48 and a quick ratio of 10.48.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, hitting the consensus estimate of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. On average, sell-side analysts predict that Taysha Gene Therapies, Inc. will post -0.35 earnings per share for the current year.

Insider Activity at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 260,047 shares of the business’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $4.51, for a total value of $1,172,811.97. Following the completion of the sale, the insider directly owned 1,006,439 shares in the company, valued at approximately $4,539,039.89. The trade was a 20.53% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.78% of the company’s stock.

Institutional Investors Weigh In On Taysha Gene Therapies

Several institutional investors and hedge funds have recently bought and sold shares of TSHA. Charles Schwab Investment Management Inc. lifted its position in shares of Taysha Gene Therapies by 15.4% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 547,128 shares of the company’s stock valued at $761,000 after acquiring an additional 72,871 shares in the last quarter. Invesco Ltd. grew its position in Taysha Gene Therapies by 83.0% during the 1st quarter. Invesco Ltd. now owns 159,899 shares of the company’s stock worth $222,000 after purchasing an additional 72,544 shares in the last quarter. Nuveen LLC acquired a new stake in Taysha Gene Therapies during the 1st quarter valued at $760,000. Wellington Management Group LLP lifted its holdings in shares of Taysha Gene Therapies by 6.8% in the first quarter. Wellington Management Group LLP now owns 625,198 shares of the company’s stock valued at $869,000 after purchasing an additional 39,604 shares in the last quarter. Finally, EntryPoint Capital LLC boosted its position in shares of Taysha Gene Therapies by 121.0% in the first quarter. EntryPoint Capital LLC now owns 135,897 shares of the company’s stock worth $189,000 after buying an additional 74,402 shares during the period. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.